PrognosDx Licenses UCLA's Epigenetics Technology

The technology "has broad potential uses in the development of cancer prognostic assays including response predictions to therapeutics as well as research tools and reagents," PrognosDx said in a statement.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories